Halozyme Therapeutics, Inc. (HALO)

Halozyme Therapeutics Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019
Period Ending	Nov 13, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Market Capitalization	7,457	4,882	7,694	5,659	5,765	2,591
Market Cap Growth	43.89%	-36.54%	35.96%	-1.84%	122.48%	23.18%
Enterprise Value	8,325	5,929	8,940	5,722	5,817	2,425
Last Close Price	58.61	36.96	56.90	40.21	42.71	17.73
PE Ratio	19.39	17.60	39.51	14.68	46.93	-
Forward PE	12.65	9.77	21.92	17.89	25.20	163.86
PS Ratio	7.89	5.89	11.65	12.76	21.54	13.22
PB Ratio	16.47	58.26	45.31	28.73	38.16	28.24
P/TBV Ratio	-	-	-	28.73	38.16	28.24
P/FCF Ratio	18.99	13.08	32.70	18.99	108.87	-
P/OCF Ratio	18.51	12.56	32.04	18.90	103.95	-
PEG Ratio	0.40	0.40	0.40	0.45	0.55	-
EV/Sales Ratio	8.79	7.15	13.54	12.91	21.74	12.37
EV/EBITDA Ratio	15.05	14.22	26.60	20.63	39.89	-
EV/EBIT Ratio	17.45	17.43	30.89	20.74	40.33	-
EV/FCF Ratio	21.20	15.88	37.99	19.20	109.86	-
Debt / Equity Ratio	3.39	18.27	9.07	4.47	2.66	4.46
Debt / EBITDA Ratio	2.73	3.59	4.54	3.15	2.71	-
Debt / FCF Ratio	3.91	4.10	6.55	2.95	7.59	-
Asset Turnover	0.47	0.46	0.45	0.53	0.47	0.39
Inventory Turnover	1.92	2.36	2.67	2.04	1.72	7.17
Quick Ratio	8.75	5.07	4.54	7.10	1.11	5.61
Current Ratio	10.36	6.64	5.65	7.91	1.32	6.35
Return on Equity (ROE)	111.83%	222.07%	110.23%	231.44%	106.33%	-42.41%
Return on Assets (ROA)	14.87%	11.89%	12.28%	20.48%	15.74%	-8.40%
Return on Capital (ROIC)	15.83%	12.78%	12.98%	21.16%	17.11%	-9.65%
Earnings Yield	5.26%	5.77%	2.63%	7.12%	2.24%	-2.79%
FCF Yield	5.27%	7.65%	3.06%	5.27%	0.92%	-3.45%
Buyback Yield / Dilution	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%
Total Shareholder Return	4.66%	4.56%	4.22%	-3.77%	1.99%	-0.51%

Source: S&P Capital IQ. Standard template. Financial Sources.